Dr Reddy’s Inks Deal for ALS Biologic Therapy COYA 302 with Coya Therapeutics

7 Dec 2023 , 11:23 AM

Dr Reddy’s Laboratories announces a development and license agreement with Coya Therapeutics for an investigational combination biologic therapy, COYA 302, targeting Amyotrophic Lateral Sclerosis (ALS).

Dr Reddy’s gains exclusive commercialization rights for COYA 302 in the US, Canada, EU, and UK for ALS patients, while Coya retains rights for markets like Japan, Mexico, and South American countries.

COYA 302 has a dual mechanism of action to suppress chronic inflammation in neurodegenerative diseases.

The agreement builds upon a previous in-licensing pact signed in early 2023 for the biosimilar abatacept as part of COYA 302’s development.

Coya will handle clinical development and seek US regulatory approval for COYA 302 for ALS, with Dr Reddy’s making an upfront payment of US$ 7.5 million, followed by additional payments upon milestones, including USFDA acceptance of the investigational new drug application.

Development and regulatory milestones payment can reach up to US$ 40 million, and Coya is eligible for sales-based milestone payments up to US$ 677.25 million linked to cumulative net sales over several years.

Dr Reddy’s will pay royalties based on a % of COYA 302 net sales, ranging from low to middle teens.
For feedback and suggestions, write to us at [e-mail]